Compare Logitech International SA (LOGI) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Logitech International SA vs Pfizer Inc — how do they compare? Logitech International SA trades at $98.15 (market cap $14.46B), while Pfizer Inc trades at $28.24 (market cap $158.56B). The key difference: Pfizer Inc is far larger — about 11× Logitech International SA's market cap, and Pfizer Inc pays the higher dividend (6.18%). Which is the better fit depends on your goals — on Pluang, investors hold Logitech International SA for 92 Days and Pfizer Inc for 158 Days on average.
| LOGI | PFE | |
|---|---|---|
Market Cap | $14.46B | $158.56B |
Volume | 349,547 | 44,138,282 |
Sector | Technology | Health |
52-Week High | $126.69 | $29.02 |
52-Week Low | $85.84 | $23.67 |
Typical Hold Time | 92 Days | 158 Days |
Enterprise Value | $12.79B | $210.06B |
Dividend Yield | 1.63% | 6.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Logitech (LOGI) trades at $98.49, down 3.61% on the day, with a neutral technical outlook and mixed analyst sentiment. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Strong profitability is evident with a net income margin of 16.28% and ROE of 35.29%. Recent news highlights product launches and partnerships, including new headsets and a collaboration with SEGA.
The outlook is balanced, with potential upside to the consensus price target of $107.00, supported by solid fundamentals and innovation. Risks include competitive pressures and macroeconomic sensitivity. Analyst consensus is divided, with 26.32% buy ratings, reflecting cautious optimism amid near-term volatility.
Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.
The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Logitech International SA
Logitech International SA is a Switzerland-based provider of personal computer and mobile accessories for navigation, video communication, and collaboration, smart home, and other applications. Its product portfolio includes mice, keyboards, charging stands, tablet cases, car mounts for mobile devices, remotes, home cameras, home switches, controllers, bluetooth speakers, surround sound, webcams, and conference cameras. It operates in a single segment namely, Peripherals. The firm generates revenue from the Americas, EMEA (Europe, Middle East, Africa), and the Asia Pacific region.
Read more on LOGI →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
